{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:43:09Z","timestamp":1785739389629,"version":"3.56.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007669","name":"Beatrice Hunter Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000521","name":"Canadian Cancer Society","doi-asserted-by":"publisher","award":["ESA-21"],"award-info":[{"award-number":["ESA-21"]}],"id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jpet.2026.104324","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:22:39Z","timestamp":1774970559000},"page":"104324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Peptide-mediated immunomodulation of tumor microenvironment in triple-negative breast cancer: A comprehensive review"],"prefix":"10.1016","volume":"393","author":[{"given":"Adnan Murad","family":"Bhayo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Marcato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4693-0724","authenticated-orcid":false,"given":"Marya","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.jpet.2026.104324_bib2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12032-024-02456-9","article-title":"The treatment landscape of triple-negative breast cancer","volume":"41","author":"Hu","year":"2024","journal-title":"Med Oncol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib3","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41598-021-04316-2","article-title":"Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer","volume":"12","author":"Hsu","year":"2022","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.jpet.2026.104324_bib4","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple negative breast cancer treatment options and limitations: future outlook","volume":"15","author":"Obidiro","year":"2023","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.jpet.2026.104324_bib5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jpet.2026.104324_bib6","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jpet.2026.104324_bib7","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.jpet.2026.104324_bib8","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40425-015-0089-6","article-title":"A new paradigm for tumor immune escape: \u03b2-catenin-driven immune exclusion","volume":"3","author":"Spranger","year":"2015","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.jpet.2026.104324_bib10","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1398-9995.2011.02610.x","article-title":"Immunotherapy with peptides","volume":"66","author":"Moldaver","year":"2011","journal-title":"Allergy"},{"issue":"25","key":"10.1016\/j.jpet.2026.104324_bib11","doi-asserted-by":"crossref","first-page":"7807","DOI":"10.7150\/thno.37194","article-title":"Peptide-based materials for cancer immunotherapy","volume":"9","author":"Zhang","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.jpet.2026.104324_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1255820","article-title":"Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer","volume":"14","author":"Huang","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.jpet.2026.104324_bib13","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3390\/cancers17071102","article-title":"Molecular subtypes and mechanisms of breast cancer: precision medicine approaches for targeted therapies","volume":"17","author":"Carvalho","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jpet.2026.104324_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221146129","article-title":"Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives","volume":"15","author":"Valenza","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jpet.2026.104324_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CMAR.S316700","article-title":"The characteristics of tumor microenvironment in triple negative breast cancer","volume":"14","author":"Fan","year":"2022","journal-title":"Cancer Manag Res"},{"issue":"11","key":"10.1016\/j.jpet.2026.104324_bib16","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.3390\/cancers16112094","article-title":"Triple negative breast cancer: molecular subtype-specific immune landscapes with therapeutic implications","volume":"16","author":"Syrnioti","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"13","key":"10.1016\/j.jpet.2026.104324_bib17","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.3390\/cancers13133357","article-title":"Tumor microenvironment: key players in triple negative breast cancer immunomodulation","volume":"13","author":"Zheng","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.jpet.2026.104324_bib18","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/ijc.34389","article-title":"The tumor microenvironment drives NK cell metabolic dysfunction leading to impaired antitumor activity","volume":"152","author":"Tumino","year":"2023","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12951-024-02622-1","article-title":"Engineering nanoparticles-enabled tumor-associated macrophages repolarization and phagocytosis restoration for enhanced cancer immunotherapy","volume":"22","author":"Gong","year":"2024","journal-title":"J Nanobiotechnology"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40164-024-00511-9","article-title":"NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice","volume":"13","author":"Hou","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104324_bib21","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ccr.2012.01.008","article-title":"Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells","volume":"21","author":"Engelhardt","year":"2012","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.jpet.2026.104324_bib22","doi-asserted-by":"crossref","first-page":"16056","DOI":"10.1021\/acsnano.3c04778","article-title":"Chimeric peptide engineered bioregulator for metastatic tumor immunotherapy through macrophage polarization and phagocytosis restoration","volume":"17","author":"Chen","year":"2023","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.jpet.2026.104324_bib23","article-title":"Peptide-drug conjugate for therapeutic reprogramming of tumor-associated macrophages in breast cancer","volume":"12","author":"Lepland","year":"2025","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s10565-025-10001-1","article-title":"Targeted nanoparticle delivery system for tumor-associated macrophage reprogramming to enhance TNBC therapy","volume":"41","author":"Dong","year":"2025","journal-title":"Cell Biol Toxicol"},{"issue":"24","key":"10.1016\/j.jpet.2026.104324_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415751","article-title":"Enhanced therapeutic effect of optimized melittin-dKLA, a peptide agent targeting M2-like tumor-associated macrophages in triple-negative breast cancer","volume":"23","author":"Kim","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jpet.2026.104324_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1522699","article-title":"The C\/EBP\u03b2 antagonist peptide lucicebtide (ST101) induces macrophage polarization toward a pro-inflammatory phenotype and enhances anti-tumor immune responses","volume":"16","author":"Scuoppo","year":"2025","journal-title":"Front Immunol"},{"issue":"35","key":"10.1016\/j.jpet.2026.104324_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202303835","article-title":"Extracellular vesicles-derived hybrid nanoplatforms for amplified CD47 blockade-based cancer immunotherapy","volume":"35","author":"Tang","year":"2023","journal-title":"Adv Mater"},{"issue":"9","key":"10.1016\/j.jpet.2026.104324_bib28","doi-asserted-by":"crossref","first-page":"9167","DOI":"10.1021\/acsnano.4c18555","article-title":"Inhibiting neutrophil extracellular trap formation through iron regulation for enhanced cancer immunotherapy","volume":"19","author":"Ye","year":"2025","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib29","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1038\/s41467-023-37580-z","article-title":"A neutrophil mimicking metal-porphyrin-based nanodevice loaded with porcine pancreatic elastase for cancer therapy","volume":"14","author":"Cui","year":"2023","journal-title":"Nat Commun"},{"issue":"27","key":"10.1016\/j.jpet.2026.104324_bib30","doi-asserted-by":"crossref","first-page":"24467","DOI":"10.1021\/acsomega.3c02415","article-title":"CXCR4-targeted necrosis-inducing peptidomimetic for treating breast cancer","volume":"8","author":"Akonnor","year":"2023","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib31","article-title":"Targeting the CXCR4\/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression","volume":"2","author":"Guo","year":"2017","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib32","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/s41467-018-05035-5","article-title":"Peptide density targets and impedes triple negative breast cancer metastasis","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"},{"issue":"18","key":"10.1016\/j.jpet.2026.104324_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814029","article-title":"Therapeutic peptide RF16 derived from CXCL8 inhibits MDA-MB-231 cell invasion and metastasis","volume":"24","author":"Chang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"24","key":"10.1016\/j.jpet.2026.104324_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202109432","article-title":"A polyvalent peptide CD40 nanoagonist for targeted modulation of dendritic cells and amplified cancer immunotherapy","volume":"34","author":"Mamuti","year":"2022","journal-title":"Adv Mater"},{"issue":"36","key":"10.1016\/j.jpet.2026.104324_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202403663","article-title":"Dual adjuvant-loaded peptide antigen self-assembly potentiates dendritic cell-mediated tumor Immunotherapy","volume":"11","author":"Kim","year":"2024","journal-title":"Adv Sci"},{"issue":"6","key":"10.1016\/j.jpet.2026.104324_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002523","article-title":"Design, synthesis and immunological evaluation of self-assembled antigenic peptides from dual-antigen targets: a broad-spectrum candidate for an effective antibreast cancer therapy","volume":"9","author":"Shi","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"22","key":"10.1016\/j.jpet.2026.104324_bib37","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.1158\/1078-0432.CCR-09-0484","article-title":"Intratumoral expression of mature human neutrophil peptide-1 mediates antitumor immunity in mice","volume":"15","author":"Wang","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jpet.2026.104324_bib38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.peptides.2017.05.006","article-title":"The frog skin host-defense peptide frenatin 2.1S enhances recruitment, activation and tumoricidal capacity of NK cells","volume":"93","author":"Pantic","year":"2017","journal-title":"Peptides"},{"key":"10.1016\/j.jpet.2026.104324_bib39","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3389\/fimmu.2018.01114","article-title":"NKp44-derived peptide binds proliferating cell nuclear antigen and mediates tumor cell death","volume":"9","author":"Shemesh","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib40","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1962592","article-title":"LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells","volume":"10","author":"Yamazaki","year":"2021","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.jpet.2026.104324_bib41","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00262-024-03732-3","article-title":"Combination of STING agonist with anti-vascular RGD-(KLAKLAK) 2 peptide as a novel anti-tumor therapy","volume":"73","author":"Czapla","year":"2024","journal-title":"Cancer Immunol Immunother"},{"issue":"17","key":"10.1016\/j.jpet.2026.104324_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202108167","article-title":"Selenopeptide nanomedicine activates natural killer cells for enhanced tumor chemoimmunotherapy","volume":"34","author":"Wei","year":"2022","journal-title":"Adv Mater"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib43","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s12916-024-03625-3","article-title":"Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells","volume":"22","author":"Thongchot","year":"2024","journal-title":"BMC Med"},{"issue":"8","key":"10.1016\/j.jpet.2026.104324_bib44","article-title":"Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer","volume":"11","author":"Baleeiro","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib45","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12935-024-03421-2","article-title":"Efficacy of MAGE-A4 long peptide as a universal immunoprevention cancer vaccine","volume":"24","author":"Cen","year":"2024","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.jpet.2026.104324_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126814","article-title":"Antitumoral effectiveness and safety of intravenous versus subcutaneous administration of immunomodulatory peptide GK-1 in a murine breast cancer model","volume":"50","author":"Hern\u00e1ndez-Aceves","year":"2025","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib47","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1760685","article-title":"Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide","volume":"9","author":"Mirando","year":"2020","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.jpet.2026.104324_bib48","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3390\/ijms20030572","article-title":"Design and synthesis of A PD-1 binding peptide and evaluation of its anti-tumor activity","volume":"20","author":"Abbas","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jpet.2026.104324_bib49","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.7150\/thno.69119","article-title":"Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death","volume":"12","author":"Moon","year":"2022","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.jpet.2026.104324_bib50","doi-asserted-by":"crossref","first-page":"9027","DOI":"10.1039\/D4RA08800J","article-title":"PD-L1 blockade peptide-functionalized NaGdF4 nanodots for efficient magnetic resonance imaging-guided immunotherapy for breast cancer","volume":"15","author":"Hu","year":"2025","journal-title":"RSC Adv"},{"issue":"14","key":"10.1016\/j.jpet.2026.104324_bib51","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3390\/cells13141193","article-title":"Peptide blockers of PD-1-PD-L1 interaction reinvigorate PD-1-suppressed T cells and curb tumor growth in mice","volume":"13","author":"Zhong","year":"2024","journal-title":"Cells"},{"issue":"Pt 2","key":"10.1016\/j.jpet.2026.104324_bib52","article-title":"Design and evaluation of \u03b1-helix-based peptide inhibitors for blocking PD-1\/PD-L1 interaction","volume":"253","author":"Rui","year":"2023","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"10.1016\/j.jpet.2026.104324_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007068","article-title":"Discovery of a novel dual-targeting D-peptide to block CD24\/Siglec-10 and PD-1\/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy","volume":"11","author":"Shen","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib54","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41420-024-01932-5","article-title":"Chemokine-derived oncolytic peptide induces immunogenic cancer cell death and significantly suppresses tumor growth","volume":"10","author":"Furukawa","year":"2024","journal-title":"Cell Death Discov"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib55","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12964-024-01731-6","article-title":"Hainanenin-1, an oncolytic peptide, triggers immunogenic cell death via STING activation in triple-negative breast cancer","volume":"22","author":"Li","year":"2024","journal-title":"Cell Commun Signal"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib56","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2054305","article-title":"PKHB1, a thrombospondin-1 peptide mimic, induces antitumor effect through immunogenic cell death induction in breast cancer cells","volume":"11","author":"Calvillo-Rodr\u00edguez","year":"2022","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13058-018-1092-x","article-title":"Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model","volume":"21","author":"Camilio","year":"2019","journal-title":"Breast Cancer Res"},{"issue":"21","key":"10.1016\/j.jpet.2026.104324_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202422874","article-title":"Self-assembly of short peptides activates specific ER-phagy and induces pyroptosis for enhanced tumor immunotherapy","volume":"64","author":"Zhang","year":"2025","journal-title":"Angew Chem Int Ed Engl"},{"issue":"11","key":"10.1016\/j.jpet.2026.104324_bib59","doi-asserted-by":"crossref","first-page":"12638","DOI":"10.1021\/acsnano.9b04181","article-title":"Co-delivery of bee venom melittin and a photosensitizer with an organic\u2013inorganic hybrid nanocarrier for photodynamic therapy and immunotherapy","volume":"13","author":"Liu","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.jpet.2026.104324_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104324_bib61","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12094-015-1373-0","article-title":"Tumor-associated macrophages in cancers","volume":"18","author":"Hu","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jpet.2026.104324_bib62","article-title":"Shaping polarization of tumor-associated macrophages in cancer immunotherapy","volume":"13","author":"Gao","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jpet.2026.104324_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202400512","article-title":"Immunomodulatory peptides for tumor treatment","volume":"14","author":"Song","year":"2025","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.jpet.2026.104324_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1248421","article-title":"Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms","volume":"11","author":"Zheng","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"issue":"9","key":"10.1016\/j.jpet.2026.104324_bib65","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/ph14090839","article-title":"Bacterial-specific aggregation and killing of immunomodulatory host defense peptides","volume":"14","author":"Nazeer","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"10.1016\/j.jpet.2026.104324_bib66","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.xphs.2024.11.006","article-title":"Controlled self-assembly of macrocyclic peptide into multifunctional photoluminescent nanoparticles","volume":"114","author":"Dissanayake","year":"2025","journal-title":"J Pharm Sci"},{"issue":"43","key":"10.1016\/j.jpet.2026.104324_bib67","doi-asserted-by":"crossref","first-page":"9041","DOI":"10.1039\/D1TB01864G","article-title":"Antibacterial activities of physiologically stable, self-assembled peptide nanoparticles","volume":"9","author":"Nazeer","year":"2021","journal-title":"J Mater Chem B"},{"issue":"11","key":"10.1016\/j.jpet.2026.104324_bib68","doi-asserted-by":"crossref","first-page":"8693","DOI":"10.1021\/acs.jmedchem.4c00005","article-title":"Secondary structure stabilization of macrocyclic antimicrobial peptides via cross-link swapping","volume":"67","author":"Nazeer","year":"2024","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.jpet.2026.104324_bib69","doi-asserted-by":"crossref","first-page":"8325","DOI":"10.1021\/acsabm.5c01243","article-title":"Self-assembled peptide nanoparticle-mediated macrophage polarization enhances anticancer efficacy of chemotherapeutics in triple-negative breast cancer","volume":"8","author":"Bhayo","year":"2025","journal-title":"ACS Appl Bio Mater"},{"issue":"14","key":"10.1016\/j.jpet.2026.104324_bib70","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.1021\/acs.nanolett.1c01210","article-title":"Detachable liposomes combined immunochemotherapy for enhanced triple-negative breast cancer treatment through reprogramming of tumor-associated macrophages","volume":"21","author":"Chen","year":"2021","journal-title":"Nano Lett"},{"issue":"20","key":"10.1016\/j.jpet.2026.104324_bib71","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2018-11-844548","article-title":"Neutrophil plasticity in the tumor microenvironment","volume":"133","author":"Giese","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jpet.2026.104324_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118699","article-title":"Tumor-associated neutrophils as new players in immunosuppressive process of the tumor microenvironment in breast cancer","volume":"264","author":"Hajizadeh","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.jpet.2026.104324_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117211","article-title":"How neutrophils shape the immune response of triple-negative breast cancer: novel therapeutic strategies targeting neutrophil extracellular traps","volume":"178","author":"Liang","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.jpet.2026.104324_bib74","doi-asserted-by":"crossref","first-page":"237","DOI":"10.21147\/j.issn.1000-9604.2017.03.10","article-title":"Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance","volume":"29","author":"Yu","year":"2017","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib75","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1038\/s41598-019-38643-2","article-title":"CXCR4 signaling regulates metastatic onset by controlling neutrophil motility and response to malignant cells","volume":"9","author":"Tulotta","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jpet.2026.104324_bib76","first-page":"88","article-title":"Human dendritic cells: ontogeny and their subsets in health and disease","volume":"6","author":"Solano-G\u00e1lvez","year":"2018","journal-title":"Med Sci (Basel)"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib77","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/cr.2016.157","article-title":"Dendritic cell-based immunotherapy","volume":"27","author":"Sabado","year":"2017","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib78","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.jpet.2026.104324_bib79","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jaci.2013.07.006","article-title":"Natural killer cell biology: an update and future directions","volume":"132","author":"Campbell","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.jpet.2026.104324_bib80","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"issue":"7","key":"10.1016\/j.jpet.2026.104324_bib81","doi-asserted-by":"crossref","first-page":"464","DOI":"10.5306\/wjco.v11.i7.464","article-title":"Why natural killer cells in triple negative breast cancer?","volume":"11","author":"Abdel-Latif","year":"2020","journal-title":"World J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib82","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40164-024-00561-z","article-title":"Natural killer cell-based cancer immunotherapy: from basics to clinical trials","volume":"13","author":"Shi","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"11","key":"10.1016\/j.jpet.2026.104324_bib83","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.4049\/jimmunol.1102267","article-title":"Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44","volume":"187","author":"Rosental","year":"2011","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.jpet.2026.104324_bib84","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41580-020-0244-x","article-title":"Molecular mechanisms and cellular functions of cGAS\u2013STING signalling","volume":"21","author":"Hopfner","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"10.1016\/j.jpet.2026.104324_bib85","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1007\/s00432-019-03036-5","article-title":"Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer","volume":"145","author":"Vihervuori","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib86","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2013 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104324_bib87","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/antib14020035","article-title":"A comprehensive review about the use of monoclonal antibodies in cancer therapy","volume":"14","author":"Justiz-Vaillant","year":"2025","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.jpet.2026.104324_bib88","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4325874","article-title":"Recent development and clinical application of cancer vaccine: targeting neoantigens","volume":"2018","author":"Pan","year":"2018","journal-title":"J Immunol Res"},{"issue":"5","key":"10.1016\/j.jpet.2026.104324_bib89","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12032-025-02739-9","article-title":"Peptide-based drugs in immunotherapy: current advances and future prospects","volume":"42","author":"Karati","year":"2025","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104324_bib90","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1871520611313020014","article-title":"The role of mesothelin in tumor progression and targeted therapy","volume":"13","author":"Tang","year":"2013","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.jpet.2026.104324_bib91","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/bs.apcsb.2017.08.001","article-title":"Multifaceted nucleolin protein and its molecular partners in oncogenesis","volume":"111","author":"Ugrinova","year":"2018","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib92","first-page":"19","article-title":"The overexpressed antigens in triple negative breast cancer and application in immunotherapy","volume":"13","author":"Jirapongwattana","year":"2020","journal-title":"Genomics Genet"},{"key":"10.1016\/j.jpet.2026.104324_bib93","article-title":"Diversity of immune checkpoints in cancer immunotherapy","volume":"14","author":"Guo","year":"2023","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.jpet.2026.104324_bib94","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.tips.2019.09.008","article-title":"The B7x immune checkpoint pathway: from discovery to clinical trial","volume":"40","author":"John","year":"2019","journal-title":"Trends Pharmacol Sci"},{"issue":"8","key":"10.1016\/j.jpet.2026.104324_bib95","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.4161\/onci.21335","article-title":"Targeting PD-1\/PD-L1 interactions for cancer immunotherapy","volume":"1","author":"Zitvogel","year":"2012","journal-title":"Oncoimmunology"},{"issue":"21","key":"10.1016\/j.jpet.2026.104324_bib96","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jpet.2026.104324_bib97","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/jamaoncol.2023.5424","article-title":"Atezolizumab in combination with carboplatin and survival outcomes in patients with metastatic triple-negative breast cancer: the TBCRC 043 phase 2 randomized clinical trial","volume":"10","author":"Lehmann","year":"2024","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104324_bib98","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00262-020-02736-z","article-title":"Pembrolizumab and atezolizumab in triple-negative breast cancer","volume":"70","author":"Kwapisz","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib99","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/PPO.0000000000000296","article-title":"Toxicities associated with PD-1\/PD-L1 blockade","volume":"24","author":"Wang","year":"2018","journal-title":"Cancer J"},{"issue":"12","key":"10.1016\/j.jpet.2026.104324_bib100","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.jpet.2026.104324_bib101","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMsb2300232","article-title":"Immune checkpoint inhibitors \u2013 the need for innovation","volume":"388","author":"Johnson","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jpet.2026.104324_bib102","first-page":"198","article-title":"Peptide drugs: a new direction in cancer immunotherapy","volume":"21","author":"Sui","year":"2023","journal-title":"Cancer Biol Med"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib103","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12967-023-04017-6","article-title":"Immunogenic cell death in cancer: concept and therapeutic implications","volume":"21","author":"Galluzzi","year":"2023","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.jpet.2026.104324_bib104","first-page":"2598","article-title":"An immunogenic cell death-related classification predicts response to immunotherapy and prognosis in triple-negative breast cancer","volume":"15","author":"Cheng","year":"2023","journal-title":"Am J Transl Res"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s43657-023-00133-x","article-title":"Investigating the immunogenic cell death-dependent subtypes and prognostic signature of triple-negative breast cancer","volume":"4","author":"Shi","year":"2024","journal-title":"Phenomics"},{"issue":"14","key":"10.1016\/j.jpet.2026.104324_bib106","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1158\/0008-5472.CAN-11-0950","article-title":"Human tumor cells killed by anthracyclines induce a tumor-specific immune response","volume":"71","author":"Fucikova","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpet.2026.104324_bib107","first-page":"341","article-title":"Therapeutic efficacy of oxaliplatin and pembrolizumab combination treatment for triple-negative breast cancer","volume":"308","author":"Chu","year":"2023","journal-title":"Stud Health Technol Inform"},{"issue":"19","key":"10.1016\/j.jpet.2026.104324_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910506","article-title":"Photodynamic therapy induced cell death mechanisms in breast cancer","volume":"22","author":"Mokoena","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.jpet.2026.104324_bib109","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.3390\/cancers15082393","article-title":"Triple-negative breast cancer: basic biology and immuno-oncolytic viruses","volume":"15","author":"Monaco","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jpet.2026.104324_bib110","article-title":"Immunogenic cell death-relevant damage-associated molecular patterns and sensing receptors in triple-negative breast cancer molecular subtypes and implications for immunotherapy","volume":"12","author":"Xu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jpet.2026.104324_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114503","article-title":"Immunogenic cell death inducer peptides: a new approach for cancer therapy, current status and future perspectives","volume":"161","author":"Aria","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"10.1016\/j.jpet.2026.104324_bib112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201220","article-title":"The anticancer peptide RT53 induces immunogenic cell death","volume":"13","author":"Pasquereau-Kotula","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib113","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/cas.13885","article-title":"CD47 agonist peptide PKHB1 induces immunogenic cell death in T-cell acute lymphoblastic leukemia cells","volume":"110","author":"Uscanga-Palomeque","year":"2019","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.jpet.2026.104324_bib114","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001926","article-title":"Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future","volume":"9","author":"Alzeibak","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526005239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526005239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:04:50Z","timestamp":1779955490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526005239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":114,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0022356526005239"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104324","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptide-mediated immunomodulation of tumor microenvironment in triple-negative breast cancer: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104324","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"104324"}}